Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

作者：Satohiro Masuda, F. Lemaı̂tre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda C. M. de Winter, Maja‐Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha L. Johnson‐Davis, Paweł K. Kunicki, Roland Lawson, Núria Lloberas, Pierre Marquet, Olga Millán, Tomoyuki Mizuno, Dirk Jan A. R. Moes, Ofelia Noceti, Michael Oellerich, Smita Pattanaik, T. Pawiński, Christoph Seger, Ron HN van Schaik, Raman Venkataramanan, Phil Walson, Jean‐Baptiste Woillard, Loralie J. Langman · 发表于：Therapeutic Drug Monitoring · 年份：2024 · DOI：10.1097/ftd.0000000000001250 · 被引用次数：15 · 研究领域：Renal Transplantation Outcomes and Treatments、Pancreatic function and diabetes、Adenosine and Purinergic Signaling

ABSTRACT: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The ...